Shanghai Haohai Biological Technology Co. Ltd (5HB) - Total Liabilities
Based on the latest financial reports, Shanghai Haohai Biological Technology Co. Ltd (5HB) has total liabilities worth €1.12 Billion EUR (≈ $1.30 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 5HB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Shanghai Haohai Biological Technology Co. Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how Shanghai Haohai Biological Technology Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Shanghai Haohai Biological Technology Co asset portfolio.
Shanghai Haohai Biological Technology Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Haohai Biological Technology Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canyon Resources Ltd
AU:CAY
|
Australia | AU$6.50 Million |
|
ETHZilla Corporation
NASDAQ:ETHZ
|
USA | $66.88 Billion |
|
Great Elm Group Inc
NASDAQ:GEG
|
USA | $71.94 Million |
|
TEKNA HOLDING ASA NK 2
F:8VB
|
Germany | €18.33 Million |
|
DCM Corp
KO:024090
|
Korea | ₩31.58 Billion |
|
FineMat Applied Materials Co Ltd
TW:6698
|
Taiwan | NT$963.77 Million |
|
GFL Limited
NSE:GFLLIMITED
|
India | Rs1.72 Billion |
|
SG Co. Ltd
KQ:255220
|
Korea | ₩124.11 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Shanghai Haohai Biological Technology Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Shanghai Haohai Biological Technology Co to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Haohai Biological Technology Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Haohai Biological Technology Co. Ltd (2016–2025)
The table below shows the annual total liabilities of Shanghai Haohai Biological Technology Co. Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.12 Billion ≈ $1.30 Billion |
-7.37% |
| 2024-12-31 | €1.20 Billion ≈ $1.41 Billion |
+10.67% |
| 2023-12-31 | €1.09 Billion ≈ $1.27 Billion |
+9.92% |
| 2022-12-31 | €990.02 Million ≈ $1.16 Billion |
+11.23% |
| 2021-12-31 | €890.07 Million ≈ $1.04 Billion |
+57.69% |
| 2020-12-31 | €564.46 Million ≈ $659.91 Million |
+13.23% |
| 2019-12-31 | €498.52 Million ≈ $582.82 Million |
-17.04% |
| 2018-12-31 | €600.90 Million ≈ $702.52 Million |
-15.20% |
| 2017-12-31 | €708.59 Million ≈ $828.42 Million |
+0.15% |
| 2016-12-31 | €707.55 Million ≈ $827.20 Million |
-- |
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more